Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Inclusion Criteria: * 1.Age older than 16 years old,gender and race no limited. * 2.Pathological diagnosis of CD19 express positive recurrent or refractory B lymphoma, satisfy any of the following a diagnosis of recurrent or refractory lymphoma: (1) According to the standard solution standardization more than four courses of treatment, tumor size \< 50% or progression;(2) According to the standard solution treatment of complete remission, after recurrence again with the original plan or the national expert consensus recommended second-line cannot again get to complete remission (3) Relapse after hematopoietic stem cell transplantation. * 3.Patients into the group needs lesions to be available for testing or evaluating disease. * 4.ECOG score reaches 0 to 1 points. * 5.Patients into the group of White Blood Cell counts in peripheral blood acuity≥ 1.0 x10\^9 / L. * 6.Estimated survival times \> 90 days. * 7.Patients have self-knowledge ability, can sign the informed consent form. Exclusion Criteria: * 1.Pregnant or lactating women. * 2.Uncontrolled infection. * 3.HIV infection, hepatitis B or C activity period. * 4.Patients who need long-term immunosuppressive therapy (Such as allergies, autoimmune diseases, GVHD, etc.) * 5.Combined activity of the central nervous system malignant tumor invasion. * 6.Abnormal coagulation function, patients with severe thrombosis. * 7\. Organ failure Heart：class Ⅱ or above. Liver：class Ⅱ or above( Refer to Classification of Wuhan Conference (1983)). Kidney: The second stage of renal insufficiency or above. Lung: class Ⅱdecreased slightly or above. Brain: The central nervous system transfer or have active lesions. * 8.Patients who have participated in other clinical trials in the past 30 days or or participate in other clinical trials at the same time. * 9.Investigator believe that the patient is not suitable to participate in the study.